Form 4: Aspira Women's Health Interim CFO Acquires 25,000 Stock Options

Aspira Women's Health's Interim CFO, John Kallassy, acquired 25,000 stock options at an exercise price of $0.84 on November 12, 2024.

Summary

• John Kallassy, the Interim CFO of Aspira Women's Health Inc., has acquired 25,000 stock options.
• The transaction occurred on November 12, 2024.
• The exercise price for these options is $0.84 per share.
• The options expire on November 12, 2027.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It is neither particularly positive nor negative, but indicates standard corporate activity.

Positives

• The acquisition of stock options by the Interim CFO could indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in publicly traded companies, including those in the healthcare sector like Aspira Women's Health.
• The exercise price of $0.84 is specific to this grant and would need to be compared to other grants to determine if it is in line with industry standards.
• The three-year expiration period is a typical timeframe for stock options.

Stakeholder Impact

• The acquisition of stock options by the Interim CFO may be viewed positively by shareholders as it aligns his interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, Aspira Women's Health, John Kallassy, CFO